Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Cassano

Showing results (21-30 of 97) with videos related to

Pageof 10
Sort By:
Expert Opinion on Pharmacotherapy|February 14, 2020
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitorsGiovanna Garufi, Antonella Palazzo, Ida Paris, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 20, 2007
Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancerCarlo Barone, Michele Basso, Giovanni Schinzari, et al.
Molecular Diagnosis & Therapy|December 10, 2015
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution AnalysisSabrina Rossi, Ettore D'Argento, Michele Basso, et al.
Oncotarget|March 2, 2018
Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urotheliumGiovanni Schinzari, Ernesto Rossi, Francesco Pierconti, et al.
Oncotarget|May 6, 2016
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysisAntonia Strippoli, Sabrina Rossi, Maurizio Martini, et al.
Annali Italiani Di Chirurgia|June 22, 2011
[Gastrointestinal stromal tumors]Marco Pericoli Ridolfini, Alessandra Cassano, Riccardo Ricci, et al.
Anticancer Research|September 6, 2017
First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) <i>Versus</i> 5-FU/LV (de Gramont Regimen)Giovanni Schinzari, Ernesto Rossi, Giuseppina Mambella, et al.
BMC Oral Health|June 3, 2023
Clinical outcomes of teeth adjacent to the site of mandibulotomy or mandibulectomy in patients with head and neck cancer: results from a multidisciplinary mono-institutional head and neck tumor boardRaffaella Castagnola, Cosimo Rupe, Gioele Gioco, et al.
Cureus|April 13, 2026
Shift in Patterns of Care and Survival Outcomes of Hepatocellular Carcinoma in a Canadian Provincial Cancer ProgramNikunj Patil, Amelia Baker, Christie Nashed, et al.
The Journal of Clinical Endocrinology and Metabolism|July 21, 2005
Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinomaMatteo Landriscina, Annarita Fabiano, Settimia Altamura, et al.
Pageof 10

Showing results (21-30 of 97) with videos related to

Sort By:
Pageof 10
Expert Opinion on Pharmacotherapy|February 14, 2020
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitorsGiovanna Garufi, Antonella Palazzo, Ida Paris, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 20, 2007
Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancerCarlo Barone, Michele Basso, Giovanni Schinzari, et al.
Molecular Diagnosis & Therapy|December 10, 2015
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution AnalysisSabrina Rossi, Ettore D'Argento, Michele Basso, et al.
Oncotarget|March 2, 2018
Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urotheliumGiovanni Schinzari, Ernesto Rossi, Francesco Pierconti, et al.
Oncotarget|May 6, 2016
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysisAntonia Strippoli, Sabrina Rossi, Maurizio Martini, et al.
Annali Italiani Di Chirurgia|June 22, 2011
[Gastrointestinal stromal tumors]Marco Pericoli Ridolfini, Alessandra Cassano, Riccardo Ricci, et al.
Anticancer Research|September 6, 2017
First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) <i>Versus</i> 5-FU/LV (de Gramont Regimen)Giovanni Schinzari, Ernesto Rossi, Giuseppina Mambella, et al.
BMC Oral Health|June 3, 2023
Clinical outcomes of teeth adjacent to the site of mandibulotomy or mandibulectomy in patients with head and neck cancer: results from a multidisciplinary mono-institutional head and neck tumor boardRaffaella Castagnola, Cosimo Rupe, Gioele Gioco, et al.
Cureus|April 13, 2026
Shift in Patterns of Care and Survival Outcomes of Hepatocellular Carcinoma in a Canadian Provincial Cancer ProgramNikunj Patil, Amelia Baker, Christie Nashed, et al.
The Journal of Clinical Endocrinology and Metabolism|July 21, 2005
Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinomaMatteo Landriscina, Annarita Fabiano, Settimia Altamura, et al.
Pageof 10